Mavrilimumab
Mavrilimumab Basic information
- Product Name:
- Mavrilimumab
- Synonyms:
-
- Mavrilimumab
- Research Grade Mavrilimumab(DHD11501)
- Mavrilimumab (anti-CD116)
- CAM 3001
- Research Grade Mavrilimumab
- CAS:
- 1085337-57-0
- MW:
- 0
- Mol File:
- Mol File
Mavrilimumab Chemical Properties
- storage temp.
- Store at -20°C
- form
- Liquid
- color
- Colorless to light yellow
Mavrilimumab Usage And Synthesis
Uses
Mavrilimumab (CAM-3001) is an investigational human IgG4 monoclonal antibody (MAb) targeting GM-CSF receptor alpha which is currently being developed for the treatment of RA. GM-CSF plays a central role in the pathogenesis of rheumatoid arthritis (RA) through the activation, differentiation, and survival of macrophages and neutrophils.
in vivo
Mavrilimumab (3–100 mg/kg, intravenously, once weekly for at least 11 weeks) inhibits GM-CSF signalling. Prolonged high-dose administration may induce neutrophilic lipid deposition, foam cell formation, cholesterol clefts, and granulomatous inflammation in alveolar macrophages. Mavrilimumab exhibits immunogenicity in crab-eating macaques, with repeated administration inducing anti-drug antibodies that accelerate drug clearance and reduce exposure levels[2].
| Animal Model: | Cynomolgus monkey models [2] |
| Dosage: | 3–100 mg/kg |
| Administration: | intravenous, once weekly for at least 11 weeks |
| Result: | Produced foam cells in the lungs. |
MavrilimumabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
- Tel
- 4008200310
- marketing@tsbiochem.com